Bioengineering of antibody fragments: challenges and opportunities
S Pirkalkhoran, WR Grabowska, HH Kashkoli… - Bioengineering, 2023 - mdpi.com
Antibody fragments are used in the clinic as important therapeutic proteins for treatment of
indications where better tissue penetration and less immunogenic molecules are needed …
indications where better tissue penetration and less immunogenic molecules are needed …
Microbial platform technology for recombinant antibody fragment production: a review
SK Gupta, P Shukla - Critical reviews in microbiology, 2017 - Taylor & Francis
Recombinant antibody fragments are being used for the last few years as an important
therapeutic protein to cure various critical and life threatening human diseases. Several …
therapeutic protein to cure various critical and life threatening human diseases. Several …
Cell-free synthesis meets antibody production: a review
M Stech, S Kubick - Antibodies, 2015 - mdpi.com
Engineered antibodies are key players in therapy, diagnostics and research. In addition to
full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant …
full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant …
Protein engineering of antibody fragments for pharmaceutical production
A Kuwahara, K Ikebukuro, R Asano - Applied Physics Reviews, 2023 - pubs.aip.org
Antibody fragments without the Fc region are attracting attention in the pharmaceutical
industry due to their high ability to penetrate solid tissues, cost-effective expression using …
industry due to their high ability to penetrate solid tissues, cost-effective expression using …
Single-chain antibody fragments: Purification methodologies
LP Malpiedi, CA Diaz, BB Nerli, A Pessoa Jr - Process Biochemistry, 2013 - Elsevier
At present, single-chain variable fragments (scFv) of antibodies are considered one of the
most important tools in human therapies. Wide applications of antibodies are being …
most important tools in human therapies. Wide applications of antibodies are being …
Recombinant antibodies: engineering and production in yeast and bacterial hosts
KJ Jeong, SH Jang, N Velmurugan - Biotechnology journal, 2011 - Wiley Online Library
After the appearance of the first FDA‐approved antibody 25 years ago, antibodies have
become major therapeutic agents in the treatment of many human diseases, including …
become major therapeutic agents in the treatment of many human diseases, including …
Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature biotechnology, 2005 - nature.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Alternative protein scaffolds as novel biotherapeutics
M Gebauer, A Skerra - Biobetters: Protein Engineering to Approach the …, 2015 - Springer
Antibody technology has gone through a long evolution. This review summarizes crucial
events during the development of this expanding field, with emphasis on recent advances in …
events during the development of this expanding field, with emphasis on recent advances in …
Production technologies for monoclonal antibodies and their fragments
DC Andersen, DE Reilly - Current opinion in biotechnology, 2004 - Elsevier
In recent years, monoclonal antibodies have emerged as an increasingly important class of
human therapeutics. A variety of forms of antibodies, including fragments such as Fabs …
human therapeutics. A variety of forms of antibodies, including fragments such as Fabs …
[HTML][HTML] Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments
Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …